Expression of Insulin-Like Growth Factor-II and Its Receptor in Pediatric and Adult Adrenocortical Tumors
Madson Q. Almeida, Maria Candida Barisson Villares Fragoso, Claudimara Ferini Pacicco Lotfi, Mariza Gerdulo Santos, Mirian Yumie Nishi, Marcia Helena Soares Costa, Antonio Marcondes Lerario, Carolina Canton Maciel, Gabriele Ebling Mattos, Alexander Augusto Lima Jorge, Berenice B. Mendonca, and Ana Claudia Latronico
Unidade de Endocrinologia do Desenvolvimento (M.Q.A., M.C.B.V.F., M.G.S., M.Y.N., M.H.S.C., A.M.L., A.A.L.J., B.B.M., A.C.L.), Laboratório de Hormônios e Genética Molecular/LIM42 da Disciplina de Endocrinologia do Hospital das Clínicas da Faculdade de Medicina, and Laboratório de Estrutura e Função Celular (C.F.P.L., C.C.M., G.E.M.), Departamento de Anatomia, Instituto de Ciências Biomédicas, Universidade de São Paulo, 05403-900 São Paulo, Brazil
Background: Adrenocortical tumors are heterogeneous neoplasms with incompletely understood pathogenesis. IGF-II overexpression has been consistently demonstrated in adult adrenocortical carcinomas.
Objectives: The objective of the study was to analyze expression of IGF-II and its receptor (IGF-IR) in pediatric and adult adrenocortical tumors and the effects of a selective IGF-IR kinase inhibitor (NVP-AEW541) on adrenocortical tumor cells.
Patients: Fifty-seven adrenocortical tumors (37 adenomas and 20 carcinomas) from 23 children and 34 adults were studied.
Methods: Gene expression was determined by quantitative real-time PCR. Cell proliferation and apoptosis were analyzed in NCI H295 cells and a new cell line established from a pediatric adre- nocortical adenoma.
Results: IGF-II transcripts were overexpressed in both pediatric adrenocortical carcinomas and adenomas. Otherwise, IGF-// was mainly overexpressed in adult adrenocortical carcinomas (270.5 ± 130.2 vs. 16.1 ± 13.3; P = 0.0001). IGF-IR expression was significantly higher in pediatric adreno- cortical carcinomas than adenomas (9.1 ± 3.1 vs. 2.6 ± 0.3; P = 0.0001), whereas its expression was similar in adult adrenocortical carcinomas and adenomas. IGF-IR expression was a predictor of metastases in pediatric adrenocortical tumors in univariate analysis (hazard ratio 1.84; 95% con- fidence interval 1.28-2.66; P = 0.01). Furthermore, NVP-AEW541 blocked cell proliferation in a dose- and time-dependent manner in both cell lines through a significant increase of apoptosis.
Conclusion: IGF-IR overexpression was a biomarker of pediatric adrenocortical carcinomas. Addi- tionally, a selective IGF-IR kinase inhibitor had antitumor effects in adult and pediatric adreno- cortical tumor cell lines, suggesting that IGF-IR inhibitors represent a promising therapy for human adrenocortical carcinoma. (J Clin Endocrinol Metab 93: 3524-3531, 2008)
A drenocortical carcinomas account for only 0.05-0.2% of all cancers, with an estimated incidence of 0.5-2 per mil- lion per year in adults (1-4). Nevertheless, a remarkably high
annual incidence of adrenocortical tumors has been reported in children younger than 15 yr from southern Brazil, where a high frequency of a germline mutation (Arg337His) of the P53 tumor
Abbreviations: CI, Confidence interval; CT, cycle threshold; FBS, fetal bovine serum; HR, hazard ratio; IGF-IR, IGF-I receptor; RLU, relative light unit.
0021-972X/08/$15.00/0 Printed in U.S.A.
Copyright @ 2008 by The Endocrine Society doi: 10.1210/jc.2008-0065 Received January 10, 2008. Accepted June 27, 2008. First Published Online July 8, 2008
suppressor gene has been reported (5-7). Differently from adults, pediatric adrenocortical tumors with apparently poor prognosis based on the histopathological features often have a better clin- ical outcome (8, 9). To date, there are limited data to define histological or molecular markers that can reliably distinguish benign from malignant adrenocortical tumors, mainly in pedi- atric patients (10).
The molecular pathogenesis of adrenocortical tumors is still poorly understood. The IGF system has an essential role in nor- mal adrenocortical cell growth and development (11, 12). In a series of comprehensive studies, Gicquel et al. (13-15) demon- strated that structural rearrangement of the 11p15 locus, typi- cally uniparental paternal isodisomy, and IGF-II overexpression were found in the great majority of adult sporadic adrenocortical carcinomas. IGF-II exerts its mitogenic effects through interac- tion with IGF-I receptor (IGF-IR) (16). Thus, overexpression of IGF-II and/or IGF-IR may trigger a cascade of molecular events that can ultimately lead to malignancy (17). However, the role of IGF-IR in adult and pediatric adrenocortical tumorigenesis re- mains to be determined.
Cytotoxic chemotherapy has been extensively used for met- astatic adrenocortical carcinoma, although response rates are generally poor (3, 18, 19). The overall response rate of the Berruti protocol (mitotane with etoposide, doxorubicin, and cisplatin) was 49%, including mainly partial responses (19). Therefore, it
is clear that current treatment protocols are not effective and that new therapies are strongly needed (20). Two microarray studies identified that up-regulation of IGF-II expression was the dom- inant change in malignant adrenocortical tumors (21, 22). Con- sequently, IGF-IR inhibition has been proposed as the most appropriated target for adrenocortical carcinoma treatment (16, 20, 23). Recently IGF-IR kinase inhibitors have been considered a new therapeutic approach for hematologic and solid malignancies (17, 23-25). A selective IGF-IR kinase in- hibitor (NVP-AEW541) was capable of effectively inhibiting li- gand-mediated IGF-IR autophosphorylation as well as protein kinase B and MAPK phosphorylation (24).
In this study, we investigated IGF-II and IGF-IR expression in pediatric and adult adrenocortical tumors. In addition, the effects of the NVP-AEW541 on proliferation and apoptosis were analyzed in NCI H295 cells and a new cell line that was estab- lished from a pediatric adrenocortical adenoma of our cohort.
Patients and Methods
The study was approved by the Ethics Committee of Hospital das Clinicas, Sao Paulo, Brazil, and informed written consent was ob- tained from all patients and/or parents. The clinical and histopatho- logical features of children and adults with adrenocortical tumors are
A
B
125
Children
10,000
Adults
p= 0.0001
100
·
IGF-II Expression (fold increase)
p =0.23
1,000
75
·
100
50
·
10
25
·
1
0
0
Adenomas (n=17)
Carcinomas (n=6)
Adenomas (n=20)
Carcinomas (n=14)
C
D
14
Children
12
·
Adults
12
p = 0.0001
10
IGF-IR Expression (fold increase)
p = 0.75
10
8
8
6
6
4
4
2
2
0
0
Adenomas (n=17)
Carcinomas (n=6)
Adenomas (n=20)
Carcinomas (n=14)
summarized in supplemental Tables 1 and 2, respectively, published as supplemental data on The Endocrine Society’s Journals Online Web site at http://jcem.endojournals.org. Samples of sporadic adre- nocortical tumors were obtained from 23 children (16 girls and 7 boys; 0.9-15 yr) and 34 adult patients (29 women and 5 men; 18-66 yr). The mean follow-up period was 57.8 ± 6.2 months. In the pe- diatric group, we observed that seven of 13 tumors with Weiss score of at least 4 had benign evolution, confirming that this isolated cri- terion is not reliable for children’s tumor classification (9). Conse- quently, the diagnosis of malignancy in this group was established in six of 23 pediatric adrenocortical tumors by an advanced tumor stage (III or IV) and/or poor clinical outcome. Adult adrenocortical tumors were classified according to Weiss criteria: 20 adrenocortical adeno- mas (Weiss score ≤3) and 14 carcinomas (Weiss score ≥4) (26). The p53 tumor suppressor gene was previously studied in 22 children and 26 adults, and the known Arg337His mutation was identified in 77 and 12% of them, respectively (7, 27).
Quantitative real-time PCR
After surgical resection, tumor fragments were immediately frozen in liquid nitrogen and stored at - 80 C until total RNA extraction using the Trizol reagent (Invitrogen, Carlsbad, CA). cDNA was generated from 1 µg of total RNA using the high capacity kit (Applied Biosystems, Foster City, CA). Quantitative real-time PCR was performed in the ABI Prism 7700 sequence detector using TaqMan gene expression assays for the gene quantification according to the manufacturer’s instructions (Applied Biosystems). The assay IDs were: IGF-II, Hs01005963_m1; IGF-IR, Hs00181385_m1; B-actin, 43263; 3-ß-hydroxysteroid dehydrogenase type II (HSD3B2) Hs00605123_m1; 11-B-hydroxylase (CYP11B1) Hs01596404_m1; 21-hydroxylase (CYP21A2) Hs00416901_g1. A cycle threshold (CT) value in the linear range of amplification was selected for each sample in triplicate and normalized to ß-actin expression levels. The relative expression levels were analyzed using the 2-44CT method, where the AACT is the difference between the selected ACT value of a particular sample and the ACT of a pool of 61 normal adrenals from autopsies (CLONTECH, Palo Alto, CA) (28). The mean expression of the target genes in the pool of normal adrenals was assigned an expression value of 1.0, and fold increase in the expression levels was determined for each tumor sample and adrenocortical tumors cell lines.
Adrenocortical cell lines
The NCI H295 cell line, previously established from an invasive pri- mary adrenocortical carcinoma, was kindly provided by Dr. Walter L. Miller (University of California, San Francisco, CA) (29). A new pedi- atric transitory cell line was obtained from a functioning adrenocortical adenoma (weight 10 g; stage I) diagnosed in a 1.1-yr-old girl with mixed syndrome (virilization and Cushing syndrome) (patient 15; supplemental Table 1). The tumor fragments (0.67 g), obtained from viable nonhem- orrhagic areas, were digested by sequential 4 mg/ml collagenase plus 1 µg/ml deoxyribonuclease I (Life Technologies, Inc., Paisley, UK), 30 min digestion and mechanical disaggregated with gentile movements in a volumetric pipette. The digested material was then filtered in a 100-um nylon filter to retain nondigested material and thereafter pelleted at 700 rpm for 10 min. Two media were used: DMEM and reduced serum medium modification of MEM (Opti-MEM I) supplemented with, re- spectively, 10 and 2% fetal bovine serum (FBS) and 1% penicillin/strep- tomycin. Initial growth, at a slow rate, occurs in both medium, and irrespective of medium used, the cells were adherent and spindle shaped. Cells were cultured in DMEM supplemented with 10% FBS for growth and steroid secretion studies. The pediatric adrenocortical adenoma cell morphological features were examined under phase-contrast micro- scope and light microscope after stained with hematoxylin and eosin. The adrenocortical tumor cell lines were maintained at 37 C in a 95% air-5% CO2 fully humidified environment and cultured in DMEM me- dium containing 10% FBS and 1% penicillin/streptomycin. All in vitro experiments and steroid analyses were performed in the fifth passage of the pediatric adrenocortical adenoma cell line.
Steroid hormone analysis
Steroid secretion was measured in 5 d clarified supernatant medium of pediatric tumor cell culture by commercial kits: cortisol and testos- terone, fluorometric assay (AutoDELFIA; Wallac, Oy, Finland); andro- stenedione, chemiluminescent enzyme immunoassay (Immulite 2000; Siemens, Siemens Medical Solutions Diagnostics, Los Angeles, CA); 17-OH progesterone, RIA (Diagnostic Systems Laboratories, Webster, TX).
Immunocytochemistry analysis
Approximately 1-2 × 104 cells were seeded onto coverslips in DMEM containing 10% FBS and fixed with formaldehyde 4% for 20 min. Immu- nocytochemistry stains were performed using antibodies against vimentin (mouse antihuman monoclonal, 1:100; Novocastra, Newcastle upon Tyne, UK) and melan A/mart 1 (prediluted mouse antihuman monoclonal clone A103; Chemicon, Temecula, CA). The immune complex was detected by immunoperoxidase staining using the Vectastain Elite ABC kit (Vector Lab- oratories, Burlingame, CA) and diaminobenzidine as previously described (30). Culture cells from human normal skin fibroblasts and human mela- noma cell line LB373-MEL were used for positive controls for vimentin and melan-A, respectively. Cell cultures incubated in nonimmune primary an- tibody yielded negative results.
A selective IGF-IR kinase inhibitor (NVP-AEW541)
NVP-AEW541, a pyrrolo[2,3-d]pyrimidine derivate highly selec- tive against IGF-IR, was kindly provided by Novartis Pharma (Basel, Switzerland) (24). Stock solution of this drug was prepared in di- methylsulfoxide and stored at -20 C.
Cell proliferation and caspase-3/7 activity assays
Adrenocortical tumor cell lines were plated in 96-well plates at a density of 20,000 cells/well. After starvation for 24 h in DMEM, cells were treated or not (control cells) with crescent concentrations of NVP- AEW541 (0.3-30 µM) with or without IGF-II (50 ng/ml; R&D Systems, Minneapolis, MN) stimulation. After 24 to 96 h, the CellTiter 96 AQue- ous One solution (Promega, Madison, WI) was added and cells incubated for 3 h. The OD was measured at 450 nm in an ELISA reader.
Apoptosis analysis was based on the caspase-3/7 activity after treat-
| Variable | Univariate analysis | ||
|---|---|---|---|
| Hazard ratio | 95% CI | P value | |
| Pediatric adrenocortical tumors | |||
| Age (yr)ª | 1.22 | 0.99-1.49 | 0.05 |
| Sexb | 0.93 | 0.17-5.1 | 0.93 |
| Mixed syndrome“ | 2.06 | 0.48-10.42 | 0.38 |
| Tumor weight (kg)ª | 16.59 | 1.54-178.9 | 0.02 |
| Weiss scoreª | 2.11 | 1.2-3.72 | 0.009 |
| IGF-IR expression levelsª | 1.84 | 1.28-2.66 | 0.01 |
| Adult adrenocortical tumors | |||
| Age (yr)ª | 0.94 | 0.88-1.01 | 0.09 |
| Sexb | 9.96 | 1.93-51.29 | 0.006 |
| Mixed syndrome“ | 2.48 | 0.59-10.39 | 0.21 |
| Tumor weight (kg)ª | 6.39 | 1.44-28.36 | 0.015 |
| Weiss scoreª | 1.74 | 1.24-2.44 | 0.001 |
| IGF-Il expression levelsª | 1.0 | 0.99-1.002 | 0.94 |
ª The variables were analyzed as continuous variables, and hazard ratio was associated with 1-unit increase in the variables.
b Female sex was the reference category.
” Cushing syndrome plus virilization.
A
B
C
D
E
F
The time of event (metastases) was defined as the time between the diagnosis of primary tumor and the first metastases. P < 0.05 was considered sig- nificant. Repeated measures of absorbance and luminescence were compared by ANOVA, fol- lowed by Bonferroni’s post hoc test. The level of significance for the Bonferroni adjusted tests was set at 0.0024.
Results
IGF-II and IGF-IR expression
IGF-II transcripts were overexpressed in both pediatric adrenocortical carcinomas and adenomas (50.8 ± 18.5 vs. 31.2 ± 3.7, respectively; P = 0.23) (Fig. 1A). Otherwise, IGF-II was mainly overexpressed in adult adrenocortical carcinomas, compared with adenomas (270.5 ± 130.2 vs. 16.1 ± 13.3; P = 0.0001) (Fig. 1B) according to previous studies (14, 15, 22). IGF-IR mRNA levels were significantly higher in childhood ad- renocortical carcinomas than adenomas (9.1 ± 3.1 vs. 2.6 ± 0.3; P = 0.0001), whereas similar IGF-IR expression levels were detected in adult adrenocortical carci- nomas and adenomas (1.6 ± 0.3 vs. 1.8 + 0.5, respectively; P = 0.75) (Fig. 1, Cand D).
Metastases were documented in six of 23 children and seven of 34 adults with adre- nocortical tumors. In pediatric adrenocor- tical tumors, tumor weight [HR 16.6, 95% confidence interval (CI) 1.54-178.9; P = 0.02], histopathological features of malig- nancy (Weiss score) (HR 2.11; 95% CI 1.2- 3.72; P = 0.009), and IGF-IR mRNA levels (HR 1.84; 95% CI 1.28-2.66; P = 0.01) were associated with a higher risk of meta- static disease in univariate analysis (Table 1). In adult adrenocortical tumors, male sex (HR 9.96; 95% CI 1.93-51.29; P = 0.006), tumor weight (HR 6.39; 95% CI 1.44-28.36; P = 0.01), and Weiss score (HR 1.74; 95% CI 1.24-2.44; P = 0.015) were associated with a higher risk of meta- static disease in univariate analysis. IGF-II expression levels were not a significant predictor of metastases (Table 1).
ment with NVP-AEW541 (0.3-30 }LM). After 3-9 h treatment, cells were incubated with the Caspase-Glo 3/7 Assay (Promega) for 1 h, and the luminescent signal was measured in a luminometer. All cell proliferation and apoptotic experiments were performed in triplicate.
Statistical analysis
All statistical analyses were performed with the SPSS software (SPSS 13.0; SPSS, Inc., Chicago, IL). Continuous data are expressed as mean ± SEM. Differences in expression levels between adenomas and carcinomas were analyzed by means of the two-tailed Mann-Whitney U test. Pre- dictive factors of metastases were identified by means of Cox propor- tional hazards regression models, which was used to estimate hazard ratios (HR) and their 95% confidence intervals in univariate analysis.
Characterization of the new pediatric adrenocortical tumor cell line
To dissect the cellular consequences of IGF-IR inhibition in pediatric and adult adrenocortical tumors, two adrenocortical cell lines were studied. The NCI H295 cell line was previously obtained from an invasive primary adrenocortical carcinoma in a 48-yr-old woman (29). To date, cell lines derived from pediatric adrenocortical tumors are lacking. Here we obtained a new pe-
diatric adrenocortical tumor cell culture from a functioning ad- renocortical adenoma. This adrenocortical adenoma cell line has continuously been growing after eight passages. Steroid secre- tion was detected in 5 d supernatant medium of the fifth sub- cultured pediatric cell culture (cortisol 238 µg/dl, testosterone 1098 ng/dl, androstenedione >8.5 ng/ml, and 17-hydroxypro- gesterone >20 ng/ml). In addition, the expression of several enzymes involved in steroid biosynthesis (3-ß-hydroxysteroid dehydrogenase type II, 11-ß-hydroxylase, 21-hydroxylase) was demonstrated by quantitative real-time PCR (data not shown).
The pediatric adrenocortical adenoma cell line had a fibro- blastoid and spindle-shaped appearance at phase-contrast microscopy and hematoxylin and eosin staining, respectively (Fig. 2, A and B). Pediatric adrenocortical adenoma cell cul- ture showed cytoplasmic immunoreactivity for melan-A in 100% of the culture cells (Fig. 2, C and D). The melan-A is a melanocytic differentiation marker, which has the useful property of staining steroid hormone-producing tumors, such as adrenocortical adenomas and carcinomas (31). A strong cytoplasmic expression of vimentin, the major intermediate filament protein of mesenchymal cells, was also detected in 100% of these adrenocortical cells (Fig. 2E and F). This ho-
mogeneity pattern of this cell culture suggests one cellular type isolated from the tumor fragments.
IGF-IR was expressed in both NCI H295 (1.5 ± 0.3) and pediatric adrenocortical adenoma (0.4 ± 0.06) cell lines, whereas IGF-II was mainly overexpressed in NCI H295 cells (42.4 ± 12.5), compared with pediatric adrenocortical adenoma cells (4.5 ± 1.1).
NVP-AEW541 effects on adrenocortical tumor cell lines
An additional implication of our findings concerns their po- tential exploitation for the identification of novel therapeutic targets. To achieve this goal, we evaluated the effects of NVP- AEW541 on blocking IGF-II stimulated proliferation of human NCI H295 and pediatric adrenocortical adenoma cells. IGF-II significantly increased proliferation of NCI H295 and pediatric adrenocortical adenoma control cells after 72 and 48 h, respec- tively (P = 0.0001). The NVP-AEW541 treatment had a signif- icant effect on proliferation reduction of NCI H295 cells at increasing concentrations of 10 µM (70 ± 10%) and 30 µM (33.3 ± 6.7%), compared with untreated cells (100 ± 6.7%) at 24 h (P = 0.0001). The treatment with this IGF-IR inhibitor significantly decreased NCI H295 cell proliferation at 0.3 µM (70.3 ± 2.7%), 1.0 µM (51.4±5.4%), 3.0µM (35.1±2.7%),
A
NCI H295 Cells
B
Pediatric Tumor Cells
140
24h
140
24h
120
120
Survival (%)
T
T
100
T
100
T
T
T
80
T
$
80
60
60
40
40
3
+
20
20
0
0
Đặt
140
48h
140
*
48h
120
T
120
Survival (%)
100
T
*
100
**
T
*
80
*
80
MA
60
60
*
40
T
40
Đặc
20
20
*
0
0
*
sệt
140
*
1
96h
140
*
1
96h
120
Survival (%)
120
100
100
złc
80
80
**
60
21g
60
40
EE
40
20
20
0
*
**
0
*
*
NVP-AEW541 (UM)
-
-
0.3
1.0
3.0
10
30
-
0.3
1.0
3.0
10
30
IGF-II 50 ng/mL
-
+
+
+
+
+
+
+
+
+
+
+
+
10 µM (18.9±0.5%), and 30µM (2.7±0.27%), compared with untreated cells (100 ± 2.7%) at 48 h (P = 0.0001). NVP- AEW541 treatment promoted a near-total reduction in NCI H295 cell proliferation at 10 and 30 µM after 96 h (Fig. 3A).
NVP-AEW541 also promoted a significant decrease of pedi- atric adrenocortical adenoma cell proliferation at 0.3 p.M (81.2 ± 3%), 1 µM (72.3 ±6%), 3 M (63.4±6%),10µM(2±0.3%), and 30 µM (2 ± 0.3%), compared with untreated cells (100 ± 5%) at 48 h (P = 0.0001). This IGF-IR inhibitor led to a pro- gressive reduction on proliferation of pediatric adrenocortical adenoma cells at 0.3 JLM (78.2 ± 5.6%), 1.0 µM (61.3 ± 1.6%), 3.0 µM (43.5 ± 2.4% OD), 10 µM (1.6 ± 0.4%), and 30 µM (1.6 ± 0.2%), compared with untreated cells (100 ± 1.6%) at 96 h (P = 0.0001) (Fig. 3B). NVP-AEW541 treatment of both adrenocortical tumor cell lines without exogenous IGF-II stim- ulation also promoted a significant reduction in cell proliferation (supplemental Fig. 1, published as supplemental data on The Endocrine Society’s Journals Online Web site at http:// jcem.endojournals.org).
The IC50 values of NVP-AEW541 were 0.2 ± 0.02 and 2.2 ± 0.06 µM for NCI H295 and for pediatric adrenocortical ade- noma cells after 96 h of treatment, respectively. The NCI H295 cells were more sensitive to NVP-AEW541, showing IC50 value at a submicromolar concentration.
We also investigated whether cells exposed to NVP-AEW541 underwent apoptosis. NCI H295 cells treated with NVP- AEW541 showed a significant increase in caspase-3/7 activity at 1.0 µM [3714 ± 248 relative light units (RLU)], 3.0 µM (5257 ± 311 RLU), 10 µM (7069 ± 801 RLU), and 30 µM (9060 ± 733 RLU), compared with untreated cells (2019 ± 329 RLU) at 3 h (P = 0.0001) (Fig. 4A). The IGF-IR inhibition in pediatric ad- renocortical adenoma cells significantly increased caspase-3/7 activity at 3.0 µM (3220.4 ± 56.2 RLU), 10 µM (4056 ± 277.9
RLU), and 30 µM (6324.6 ± 198.3 RLU), compared with un- treated cells (1732.9 ± 61.4 RLU) at 9 h (P = 0.0001) (Fig. 4B).
Discussion
The IGF signaling pathway plays an important role in the reg- ulation of adrenal growth and differentiation (17). Binding of ligands to the IGF-IR or its own overexpression initiates a cas- cade of events, leading to stimulation of proliferation, angiogen- esis, apoptosis, and inhibition of metastases (32). Indeed, in- creased expression of IGF-II and/or IGF-IR have been documented in various malignant tumors (33, 34). A strong overexpression of IGF-II is a dominant finding in adult adreno- cortical cancer, occurring in approximately 83% of malignant adrenocortical tumors (14). Nonetheless, very few studies about IGF-II expression in pediatric adrenocortical tumors were re- ported (35, 36). We demonstrated that IGF-II expression was deregulated in a similar manner in both pediatric adrenocortical adenomas and carcinomas.
IGF-IR overexpression was previously demonstrated in adult adrenocortical carcinomas but not adrenocortical hyperplasias and adenomas (37, 38). In this study, we identified that IGF-IR expression was similar in benign and malignant adult adreno- cortical tumors. Otherwise, a strong increase in IGF-IR expres- sion was identified only in pediatric adrenocortical carcinomas. In our cohort, IGF-IR expression was a predictor of metastases in children with adrenocortical tumors. The mechanisms respon- sible for enhanced IGF-IR expression in pediatric adrenocortical tumors are still unclear. Changes in IGF system expression in cancerous cells may occur as a result of loss or altered expression of tumor suppressor genes (17). In normal cells, expression of wild-type P53 was shown to inhibit IGF-IR expression, whereas
A
B
10,000
NCI H295 Cells
*
10,000
Pediatric Tumor Cells
Caspase-3/7 activity (Relative light units)
8,000
3h Treatment
8,000
6h Treatment
6,000
*
6,000
4,000
*
4,000
*
*
*
*
T
2,000
T
2,000
0
0
10,000
NCI H295 Cells
10,000
Pediatric Tumor Cells
Caspase-3/7 activity (Relative light units)
8,000
6h Treatment
9h Treatment
*
8,000
*
*
6,000
*
6,000
*
4,000
*
4,000
*
-
2,000
2,000
T
0
0
Control
0.3
1.0
3.0
10
30
Control
0.3
1.0
3.0
10
30
NVP-AEW541 (UM)
NVP-AEW541 (UM)
mutant P53 up-regulates IGF-IR expression in different tumors (39). In our cohort, 17 of 22 children with adrenocortical tumors (77%) harbored the Arg337His P53 mutation. Nevertheless, IGF-IR expression levels were not associated with the presence of this mutation (data not shown). Therefore, other molecular events, like IGF-IR gene amplification, may be involved in IGF-IR overexpression in pediatric adrenocortical tumors.
Adrenocortical carcinoma remains a disease of poor progno- sis, with little expectation of long-term survival if complete sur- gical removal is not achieved (3). Therefore, the development of new inhibitory drugs that can target signaling pathways involved in adrenocortical tumorigenesis is strongly necessary. Although kinase inhibitors hold much promise for cancer therapy, their successful application requires preclinical strategies to identify molecular markers that define susceptible tumor subtypes. Anal- ysis of tumor-derived cell lines provides an effective system for establishing the link between specific tumor molecular aspects and the response to molecular target drugs (40). We established a new transitory cell culture derived from a human pediatric adrenocortical adenoma, thus permitting the study of a specific signaling pathway that may interfere with adrenocortical tumor growth in children. We demonstrated that NVP-AEW541, a se- lective IGF-IR kinase inhibitor, was able to block cell prolifer- ation in a dose- and time-dependent manner in two distinct hu- man adrenocortical tumor cell lines. The inhibitory effects of the NVP-AEW541 were induced by a significant induction of apo- ptotic rate. In addition to antiproliferative and proapoptotic ef- fects, the IGF-IR inhibition could also increase the efficacy of other therapeutic modalities, such as radiotherapy, in breast can- cer cells (41).
The ability of the NVP-AEW541 to potently induce apoptosis was previously demonstrated in several cell lines by determining functional and morphological changes and caspase activation as well as fragmentation of nuclear DNA (25, 42, 43). Furthermore, NVP-AEW541 also inhibits cell cycle progression, inducing spe- cific G1 arrest (25, 42). Regarding NVP-AEW541 sensitivity, NCI H295 cells showed an IC50 value comparable with that of the most sensitive cells, such as Ewing’s sarcoma and neuroblas- toma cell lines (25, 44). The level of sensitivity of the pediatric adrenocortical tumor cells was similar to that of hepatocellular carcinoma and gastrointestinal tumor cells (42, 43).
In conclusion, IGF-IR overexpression was a biomarker of pediatric adrenocortical carcinomas. In addition, we demon- strated that a selective IGF-IR kinase inhibitor had antitumor effects in adult and pediatric adrenocortical tumor cell lines, suggesting that IGF-IR inhibitors represent a promising therapy for human adrenocortical carcinoma.
Acknowledgments
We are in debt to Lourdes C. Martins (Department of Preventive Med- icine, University of Sao Paulo) for the statistical review. We thank Valeria S. Lando and the staff of Laboratorio de Hormonios e Genetica Molec- ular LIM-42 for the steroid hormone analysis.
Address all correspondence and requests for reprints to: Madson Queiroz Almeida, M.D., Unidade de Endocrinologia do Desenvolvi-
mento e Laboratorio de Hormonios e Genetica Molecular LIM-42, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Av. Dr. Eneas de Carvalho Aguiar, 155, 20 andar Bloco 6, 05403-900 Sao Paulo, SP, Brasil. E-mail: madsonalmeida@ gmail.com; anacl@usp.br.
This work was supported by Grants 05/04726-0; 06/00244-3 from the Fundação de Amparo à Pesquisa do Estado de São Paulo (to M.Q.A.) and by Grants 300469/2005-5 (to A.C.L.) and 300828/2005-5 (to B.B.M.) from the Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Disclosure Statement: We declare no duality of financial interest or direct or indirect conflict of interest on the part of any author of this manuscript.
References
1. Latronico AC, Chrousos GP 1997 Extensive personal experience: adrenocor- tical tumors. J Clin Endocrinol Metab 82:1317-1324
2. Libe R, Fratticci A, Bertherat J 2007 Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 14:13-28
3. Allolio B, Fassnacht M 2006 Clinical review: adrenocortical carcinoma: clin- ical update. J Clin Endocrinol Metab 91:2027-2037
4. Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, Dousset B, Bertagna X, Bertherat J 2006 Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 91:2650-2655
5. Sandrini R, Ribeiro RC, DeLacerda L 1997 Childhood adrenocortical tumors. J Clin Endocrinol Metab 82:2027-2031
6. Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, DeLacerda L, Rabin M, Cadwell C, Sampaio G, Cat I, Stratakis CA, Sandrini R 2001 An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 98: 9330-9335
7. Latronico AC, Pinto EM, Domenice S, Fragoso MC, Martin RM, Zerbini MC, Lucon AM, Mendonca BB 2001 An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in chil- dren and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab 86:4970-4973
8. Mendonca BB, Lucon AM, Menezes CAV, Saldanha LB, Latronico AC, Zer- bini C, Madureira G, Domenice S, Albergaria MAP, Camargo MHA, Halpern A, Liberman B, Arnhold IJP, Bloise W, Andriolo A, Nicolau W, Silva FAQ, Wroclaski E, Arap S, Wajchenberg BL 1995 Clinical, hormonal and patho- logical findings in a comparative study of adrenocortical neoplasms in child- hood and adulthood. J Urol 154:2004-2009
9. Wieneke JA, Thompson LD, Heffess CS 2003 Adrenal cortical neoplasms in the pediatric population: a clinicopathologic and immunophenotypic analysis of 83 patients. Am J Surg Pathol 27:867-881
10. Almeida MQ, Latronico AC 2007 The molecular pathogenesis of childhood adrenocortical tumors. Horm Metab Res 39:461-466
11. Ilvesmaki V, Blum WF, Voutilainen R 1993 Insulin-like growth factor binding proteins in the human adrenal gland. Mol Cell Endocrinol 97:71-79
12. Weber MM, Fottner C, Schmidt P, Brodowski KM, Gittner K, Lahm H, Engelhardt D, Wolf E 1999 Postnatal overexpression of insulin-like growth factor II in transgenic mice is associated with adrenocortical hyperplasia and enhanced steroidogenesis. Endocrinology 140:1537-1543
13. Gicquel C, Bertagna X, Schneid H, Francillard-Leblond M, Luton JP, Girard F, Le Bouc Y 1994 Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab 78:1444-1453
14. Gicquel C, Raffin-Sanson ML, Gaston V, Bertagna X, Plouin PF, Schlumberger M, Louvel A, Luton JP, Le Bouc Y 1997 Structural and functional abnormal- ities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab 82:2559-2565
15. Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Bertherat J, Chapuis Y, Duclos JM, Schlumberger M, Plouin PF, Luton JP, Le Bouc Y 2001 Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 61:6762-6767
16. Logie A, Boulle N, Gaston V, Perin L, Boudou P, Le Bouc Y, Gicquel C 1999 Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. J Mol Endocrinol 23:23-32
17. Samani AA, Yakar S, LeRoith D, Brodt P 2007 The role of the IGF system
in cancer growth and metastasis: overview and recent insights. Endocr Rev 28:20-47
18. Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L 1998 Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced ad- renocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer 83:2194-2200
19. Berruti A, Terzolo M, Sperone P, Pia A, Casa SD, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero F, Reimondo G, Angeli A, Dogliotti L 2005 Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adre- nocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12:657-666
20. Kirschner LS 2006 Emerging treatment strategies for adrenocortical carci- noma: a new hope. J Clin Endocrinol Metab 91:14-21
21. Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, Smith AL, Sanders D, Aljundi RT, Gauger PG, Thompson NW, Taylor JM, Hanash SM 2003 Distinct transcriptional profiles of adrenocortical tumors uncov- ered by DNA microarray analysis. Am J Pathol 162:521-531
22. de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R, Bertherat J, Bertagna X, Plouin PF, Baudin E, Berger F, Gicquel C, Chabre O, Feige JJ 2005 Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 90:1819-1829
23. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, Garcia- Echeverria C, Pearson MA, Hofmann F, Anderson KC, Kung AL 2004 Inhi- bition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5:221-230
24. Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, Gao J, Brueggen J, Capraro HG, Cozens R, Evans DB, Fabbro D, Furet P, Porta DG, Liebetanz J, Martiny-Baron G, Ruetz S, Hofmann F 2004 In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5:231-239
25. Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, Croci S, Perdichizzi S, Zambelli D, Serra M, Garcia-Echeverria C, Hofmann F, Picci P 2005 Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 65: 3868-3876
26. Weiss LM 1984 Comparative histologic study of 43 metastasizing and non- metastasizing adrenocortical tumors. Am J Surg Pathol 8:163-169
27. Pinto EM, Billerbeck AE, Fragoso MC, Mendonca BB, Latronico AC 2005 Deletion mapping of chromosome 17 in benign and malignant adrenocortical tumors associated with the Arg337His mutation of the p53 tumor suppressor protein. J Clin Endocrinol Metab 90:2976-2981
28. Livak KJ, Schmittgen TD 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2[-AAC(T)] method. Methods 25:402-408
29. Gazdar AF, Oie HK, Shackleton CH, Chen TR, Triche TJ, Myers CE, Chrousos GP, Brennan MF, Stein CA, La Rocca RV 1990 Establishment and character- ization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res 50:5488-5496
30. Lotfi CF, Armelin HA 2001 cfos and cjun antisense oligonucleotides block
mitogenesis triggered by fibroblast growth factor-2 and ACTH in mouse Y1 adrenocortical cells. J Endocrinol 168:381-389
31. Ghorab Z, Jorda M, Ganjei P, Nadji M 2003 Melan A (A103) is expressed in adrenocortical neoplasms but not in renal cell and hepatocellular carcinomas. Appl Immunohistochem Mol Morphol 11:330-333
32. Wang Y, Sun Y 2002 Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis. Curr Cancer Drug Targets 2:191-207
33. Perks CM, Holly JM 2003 The insulin-like growth factor (IGF) family and breast cancer. Breast Dis 18:45-60
34. Wrobel G, Roerig P, Kokocinski F, Neben K, Hahn M, Reifenberger G, Lichter P 2005 Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer 114:249-256
35. Wilkin F, Gagne N, Paquette J, Oligny LL, Deal C 2000 Pediatric adrenocor- tical tumors: molecular events leading to insulin-like growth factor II gene overexpression. J Clin Endocrinol Metab 85:2048-2056
36. West AN, Neale GA, Pounds S, Figueredo BC, Rodriguez Galindo C, Pianovski MA, Oliveira Filho AG, Malkin D, Lalli E, Ribeiro R, Zambetti GP 2007 Gene expression profiling of childhood adrenocortical tumors. Cancer Res 67:600-608
37. Weber MM, Auernhammer CJ, Kiess W, Engelhardt D 1997 Insulin-like growth factor receptors in normal and tumorous adult human adrenocortical glands. Eur J Endocrinol 136:296-303
38. Kamio T, Shigematsu K, Kawai K, Tsuchiyama H 1991 Immunoreactivity and receptor expression of insulinlike growth factor I and insulin in human adrenal tumors. An immunohistochemical study of 94 cases. Am J Pathol 138:83-91
39. Werner H, Karnieli E, Rauscher FJ, LeRoith D 1996 Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 93:8318-8323
40. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J 2007 Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci USA 104: 19936-19941
41. Wen B, Deutsch E, Marangoni E, Frascona V, Maggiorella L, Abdulkarim B, Chavaudra N, Bourhis J 2001 Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells. Br J Cancer 85:2017-2021
42. Hopfner M, Huether A, Sutter AP, Baradari V, Schuppan D, Scherubl H 2006 Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hep- atocellular carcinoma cells. Biochem Pharmacol 71:1435-1448
43. Hopfner M, Baradari V, Huether A, Schofl C, Scherubl H 2006 The insulin- like growth factor receptor 1 is a promising target for novel treatment ap- proaches in neuroendocrine gastrointestinal tumours. Endocr Relat Cancer 13:135-149
44. Tanno B, Mancini C, Vitali R, Mancuso M, McDowell HP, Dominici C, Raschella G 2006 Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo. Clin Cancer Res 12:6772-6780